Tectonic Therapeutic reports favorable Phase 1a results for TX2100 in HHT
The company said TX2100 was generally safe and well tolerated with no serious safety signals in single-dose cohorts, and plans open-label Phase 1b by year-end 2026 and placebo-controlled Phase 2 in early 2027.